The Major Vault Protein (MVP), a New Multidrug Resistance Associated Protein, is Frequently Expressed in Multiple Myeloma

Publisher Website
Google Scholar
Abstract
The major vault protein (MVP), a ribonucleoprotein complex which mediates the transport of xenobiotic toxins, has been implicated in multidrug resistance (MDR) not mediated by p-glycoprotein (P-gp) or multidrug resistance related protein (MRP). We evaluated, via immuno-histochemistry, the presence of MVP in plasma cells of myeloma patients. Among 73 patients registered with the Southwest Oncology Group (SWOG), 52 patients (74%) were positive for MVP. The presence of MVP and P-gp were significantly associated (p5%) was significantly associated with shorter 0s (log rank p-value=0.0002). The collective work indicates that MVP protein is common and abundant in myeloma with potential relevance to therapeutic response.